Infection
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?
As trials of phage therapies for bacterial infections increase, the European Medicines Agency has proposed quality requirements in marketing applications for such products. Companies in this field include Locus Biosciences, Armata Pharmaceuticals, TechnoPhage, Phiogen, Medea Biopharma and BiomX.
Charles Cooper, CMO of the diagnostics firm bioMérieux, talks to In Vivo about the vital nature of partnerships to fight the global AMR crisis.



